Analysts anticipate Humana will report Q2 2026 revenue of approximately $30.85 billion and EPS of $6.22, with the current stock price of $342.15 trailing the consensus analyst price target of $415.00.
The central narrative for this report is the Medical Benefit Ratio (MBR), as investors weigh whether the company has successfully managed rising medical utilization costs within its Medicare Advantage business.
Humana has faced significant headwinds over the past year due to higher-than-expected outpatient care trends and regulatory shifts in government reimbursement rates. Markets are specifically seeking confirmation that 2026 premium adjustments and benefit redesigns are beginning to restore the company's historical margin profile.